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Abstract
CPD-associated peritonitis is a leading cause of morbidity and mortality for ESRD patients
maintained on CPD therapy. The percentage of ESRD patients maintained on CPD therapy is
declining. The reasons are unclear, but may be due to concerns about CPD-associated peritonitis.
The incidence of CPD-associated peritonitis has decreased largely attributed to technical advances
and the identification of risk factors including exit-site infection, colonization with Staphylococcus
aureus and depression.
The typical spectrum of organisms causing peritonitis include gram-positive organisms (67%), gram-
negative organisms (28%), fungi (2.5%) or anaerobic organisms (2.5%). Culture-negative episodes
do occur: up to 20% of the episodes of peritonitis in some series are culture-negative. The
treatment of CPD associated peritonitis is rather standardized with current recommendations by
the International Society of Peritoneal Dialysis universally adopted. Approximately 80% of the
patients developing peritonitis will respond to antimicrobial therapy and remain on CPD therapy,
while 10 to 15% of the patients require catheter removal and transfer to hemodialysis.
Approximately 6% of the patients expire as a result of peritonitis. The outcome is different based
on organism with gram-negative and fungal episodes having a worse outcome than gram-positive
episodes.
The development of CPD-associated peritonitis can be linked to traditional risk factors such as
exit-site infection and poor technique. Bacterial biofilm has also been suggested as a cause of
peritonitis. Our current antimicrobial protocols may not permit adequate dosing to penetrate the
biofilm and be a reason for recurrent or repeat episodes of peritonitis.
It is important that we improve our understanding of factors responsible for the development and
outcome of CPD-associated peritonitis in order for this renal replacement therapy to remain a
viable option for patients with ESRD.
Introduction
The United States Renal Data System (USRDS) tracks all
patients with end stage renal disease (ESRD) in the United
States. The 2005 USRDS report indicated that there were
323, 926 prevalent patients in the United States main-
tained on dialysis therapy [1]. Only 25,825 (8.6%) of
these prevalent patients were maintained on chronic peri-
toneal dialysis (CPD) therapy. This percentage of patients
has been declining steadily over the last few years, from a
peak of 15% in 1994 [2]. The reasons for the decline in the
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utilization of CPD therapy in the United States are not
clear and have attracted considerable interest. Attention
has focused on concerns with the structural organization
of dialysis facilities, problems with the education of the
patient with chronic kidney disease, problems with the
training of nephrologists, and problems with technique
failure, infection and patient mortality [3].
The high mortality rate of dialysis patients has been an
area of much concern amongst nephrologists. Mortality
attributed to infections, as well as hospital days related to
infections have been noted to be significantly higher for
patients maintained on peritoneal dialysis compared to
patients maintained on hemodialysis [1]. CPD-associated
peritonitis is the most common infection in CPD patients
and has been noted to be not only a major cause of mor-
bidity and mortality but also the leading cause of tech-
nique failure of patients maintained on CPD [4].
CPD-associated infections have thus received much atten-
tion and have been the subject of extensive investigation.
Interest has been focused on strategies to reduce the inci-
dence of infections, better understand the risk factors that
predispose patients to infections, and develop better ther-
apeutic strategies for treating these infections.
Incidence and risk factors
The rate of CPD-associated peritonitis has decreased since
CPD therapy was first described. Initial infection rates
were more frequent than one infection per 12 patient
months of therapy. Centers now routinely report infection
rates of less than one episode in 24 patient months and as
low as 1 episode in 60 patient months [5].
The improved rates have been attributed to technical
advances as well as to the identification of risk factors
associated with the development of CPD-associated peri-
tonitis. For example, the development of the Ultra Twin
Bag (Baxter) with its closed connectology immediately led
to a reduction in the peritonitis rate when compared to
the Ultra-Y-Set system that involved dual manual spiking
procedures (1 episode/33.9 patient months vs. 1 episode/
11.7 patient months) [6].
The association between a peritoneal catheter exit-site
infection and the development of peritonitis has been
well established. Twardowski and Prowant have devel-
oped explicit definitions of exit-site infections [7]. These
clinicians suggest that aseptic techniques with nonirritat-
ing solutions be used and that catheters be immobilized.
Furthermore, they have provided detailed protocols for
caring for infected exit-sites. Others have advocated use of
antibiotic creams, including mupirocin and gentamicin
directly to the exit-site in the prevention of exit-site infec-
tion and peritonitis [8-10].
Nasal colonization with organisms such as Staphylcoccus
aureus has also been linked to the development of perito-
nitis [11,12]. The Mupirocin Study Group randomized
patients with nasal S aureus carriage to intranasal mupi-
rocin or placebo with a significant reduction in exit-site
infections with S aureus in the mupirocin treated group,
yet no difference in the peritonitis rates [12]. The persist-
ent nature of Staphylococcus aureus nasal colonization and
the undesirability of applying mupirocin routinely to the
nostrils lead to the use of mupirocin directly applied at the
exit-site [8,9]. Bernardini et al prospectively randomized
mupirocin applied to the exit-site versus oral rifampin
with an equal benefit noted with either approach [8]. This
group also showed that gentamicin cream was equally
effective in preventing S aureus infections, but better at the
prevention of gram-negative infections [10]. As a result,
most centers have adopted either mupirocin or gentamy-
cin cream as part of routine preventative care.
Depression, the most common psychological disorder
among patients with ESRD has been linked to peritonitis
in CPD patients. Our group has shown in a retrospective
study that patients with more than one episode of perito-
nitis had significantly higher depression and anxiety than
did patients with zero or one episodes of peritonitis [13].
We also showed in a prospective study that patients who
manifested depressive symptoms, as indicated by a Beck
Depression Inventory score of ≥ 11, had a significantly
higher peritonitis rate than those patients with lesser
amounts of depressive symptoms, after controlling for
age, ethnicity and various co-morbid diseases [14]. Fur-
ther studies are needed to clarify the impact of depression,
that is potentially treatable, on the development of perito-
nitis.
Definitions
CPD-associated peritonitis is defined as the presence of
cloudy peritoneal effluent with 100 white blood cells/
mm3 with greater than 50% polymorphonuclear cells.
Abdominal pain and fever may or may not accompany
these clinical and laboratory findings.
Episodes of peritonitis are determined to be recurrent or
relapsing if the same organism with the same sensitivity
pattern is isolated within the four-week period following
the completion of a standard 2 week course of antimicro-
bial therapy. Repeat episodes of peritonitis are determined
to occur if the patient develops peritonitis with the same
organism and same sensitivity pattern greater than four
weeks after the completion of antimicrobial therapy. Fin-
kelstein et al using Spearman correlation testing found
that 80% of CPD patients developing more than one epi-
sode of peritonitis had at least one repeat infection with
the same organism [15]. In particular, there was a mark-
edly increased statistically likelihood that both S. epider-Annals of Clinical Microbiology and Antimicrobials 2006, 5:6 http://www.ann-clinmicrob.com/content/5/1/6
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midis and S. aureus would follow themselves as causative
organisms for peritonitis.
Polymicrobial peritonitis is defined as the development of
peritonitis with more than one organism and accounts for
six percent of all episodes of peritonitis. Our group
reviewed 80 episodes of polymicrobial peritonitis and
found that 80% of the patients remain on CPD therapy
which is typical for the more common single organism
peritonitis [16]. And, surprisingly, underlying gastrointes-
tinal disease was not common among the patients devel-
oping polymicrobial peritonitis. Nosocomial  peritonitis,
accounting for less than 1% of the episodes of peritonitis,
is defined as the development of peritonitis in a hospital
setting when no other infection was present at the time of
admission (which may have lead to peritonitis) and there
was no evidence that peritonitis was present at the time of
admission. In our series, Nosocomial peritontitis devel-
oped in 5% of admissions of CPD patients over a one-year
period with 42% of these patients expiring while being
treated for the episode of peritonitis [17].
Death due to peritonitis has been defined as death due to
sepsis, death occurring with a positive peritoneal dialysis
culture, death within 14 days after onset of peritonitis or
death occurring during hospitalization for any patient
admitted with peritonitis [18]. Death attributed to perito-
nitis occurs in one to six percent of patients. It is worth
noting that incidence of death associated with peritonitis
has not improved despite a decrease in the peritonitis rate.
Host defense in CPD-associated peritonitis
The peritoneal host defenses, including the peritoneal
macrophages, mesothelial cells, fibroblasts and recruited
neutrophils, are important in maintaining the perito-
neum's response to infection. The peritoneal macrophage
is the first responder along with the mesothelial cell; each
stimulates a variety of cytokines and chemokines to attract
neutrophils to the peritoneum. Several critical factors are
then involved in the recruitment process to mediate an
effective deployment of neutrophils [19].
It is well documented that the peritoneal dialysis solution
itself can alter the immune response of the peritoneum
[20]. Conventional dialysis solutions contain high lactate
and glucose concentrations, a low pH, and glucose degra-
dation products (that accumulate during the heat-sterili-
zation process). These alter the peritoneal membrane's
ability to initiate and sustain an immune response. Newer
biocompatible solutions may offer a improved ability of
the patient to combat bacterial infections. One study has
suggested that patients using the newer, more biocompat-
ible solutions have a significantly lower rate of peritonitis
when compared to patients using traditional dextrose
based solutions [21]
Spectrum of organisms
The spectrum of organisms isolated among patients with
CPD peritonitis is well described [22]. The typical spec-
trum of isolates include gram-positive organisms (67%),
gram-negative organisms (28%), fungal (2.5%) or anaer-
obic organisms (2.5%). Staphylococcus aureus accounts for
about 15% of the isolates and Staphylococcus epidermidis
accounts for about 22% of the isolates. Recently, there has
been a decline in the incidence of peritonitis caused by
both Staphylococcus aureus and Staphylococcus epidermidis
organisms, related in part to improved exit-site care and in
part to newer techniques [5,22].
However, positive cultures are not obtained in all perito-
nitis episodes. In fact, in some series, up to 20% of the epi-
sodes of peritonitis are culture-negative [23]. The
importance of adequate culturing techniques, therefore,
cannot be overemphasized [24].
Antibiotic resistant organisms deserve mention in regard
to their impact on outcomes of CPD-associated peritoni-
tis. There have been reports of vancomycin resistant ente-
rococci, vancomycin intermediate sensitive staphylococci
and multi-drug resistant gram-negative organisms [25-
27]. The poorer outcomes, in terms of morbidity and mor-
tality, associated with these organisms deserves mention
Treatment
Several antibiotic protocols exist for the treatment of
CPD-associated peritonitis. The International Society of
Peritoneal Dialysis has developed extensive guidelines for
the treatment of CPD associated peritonitis [24]. [A com-
plete listing of all antibiotic protocols can be obtained by
contacting http://www.ispd.org.] The cornerstones of the
management of CPD associated peritonitis include broad
empiric antibiotic coverage for both gram-positive and
gram-negative organisms. Once the organisms and sensi-
tivities are identified, appropriate adjustments in antibiot-
ics should be made. Antibiotics are generally given
intraperitoneally and continued for a minimum of two
weeks. Persistent high white blood cell counts in the peri-
toneal fluid after 4 days of appropriate antibiotic therapy
typically warrants consideration for catheter removal with
temporary hemodialysis and intravenous antibiotics [24].
Outcome
Several large outcome studies have noted that CPD asso-
ciated peritonitis can be successfully cured with eradica-
tion of the infection and continuation of CPD therapy in
80–85% of the episodes of peritonitis. Approximately 10–
15% of patients require catheter removal and transfer to
hemodialysis during an episode of peritonitis [28,29].
In one to six percent of patients (quote studies), death has
been associated with the peritonitis episode [28] Peritoni-Annals of Clinical Microbiology and Antimicrobials 2006, 5:6 http://www.ann-clinmicrob.com/content/5/1/6
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tis, thus, may play a contributory role in the high mortal-
ity rate associated with dialysis therapy. For example,
Fried et al noted a significant association of peritonitis
with death in 15.8% of the CPD patients between 1979
and 1994 [18]. Inflammatory cytokines, including C-
Reactive Protein, have been observed to be significantly
elevated in the initial 48 hours of peritonitis and may
remain elevated for weeks after the peritonitis episode
[30]. This marker, linked to cardiovascular mortality, may
provide a link between peritonitis and the associated mor-
tality. Although peritonitis rates have decreased signifi-
cantly in recent years, the outcome of peritonitis has not
significantly improved despite the technical advances in
CPD technology.
The outcomes observed for CPD-associated peritonitis
varies depending on the organisms responsible for the
infection. Goldie et al examined the outcome of 55 epi-
sodes of fungal peritonitis occurring in our unit [31]. 27
(49%) continued CPD therapy following the completion
of anti-fungal therapy and the removal of the peritoneal
catheter, 17 (31%) transferred to hemodialysis and 11
(20%) expired. Both our group and Bunke et al noted that
patients developing gram-negative peritonitis had a worse
outcome than did patients developing gram-positive peri-
tonitis [28,29]. In our analysis 97% of the patients devel-
oping gram-positive peritonitis remained on CPD therapy
at 2 weeks while only 73% of patients developing gram-
negative peritonitis remained on CPD therapy (p < 0.05).
Patients developing gram-negative peritonitis were signif-
icantly more likely than patients developing gram-posi-
tive peritonitis to be hospitalized (74% vs 24%, p <
0.001) and expire within six months after the onset of
peritonitis (21% vs 9%, p < 0.05). Peritonitis with Staphy-
lococcus aureus also contributes to the poor outcome asso-
ciated with peritonitis. Krishnan et al noted that only
68.6% of Staphylococcus aureus peritonitis resolved with
continued CPD therapy compared to 94.2% of the other
gram-positive episodes resolved [32].
The indwelling silastic peritoneal catheter has been impli-
cated as a source and nidus of infection. It is necessary to
remove the peritoneal catheter for certain types of perito-
nitis, such as those caused by Pseudomonas, fungi, myco-
bacterium and vancomycin-resistant enterococci [24]. In
addition, it has been recommended that the peritoneal
catheter be removed for patients who develop recurrent
peritonitis with the same organism, patients who fail to
respond to appropriate antibiotic therapy with four days,
and patients who develop repeat infections [24].
Technique failure for patients who undergo peritoneal
catheter removal is high, since it is often difficult to re-
establish a viable peritoneal access. For example, our
group noted a guarded outcome following the removal of
the peritoneal catheter for peritonitis [33]. Only 47% of
the patients were able to successfully return to CPD ther-
apy. Furthermore, 23% of the patients died following
catheter removal and another 26% died in the first year
following the reinsertion of the peritoneal catheter. Simi-
larly, Szeto et al noted that only 51% of the patients who
had the peritoneal catheter removed during an episode of
peritonitis had the catheter reinserted to continue CPD
therapy and that only 25% of these patients remained on
CPD therapy 24 months after catheter removal [34].
CPD modality and peritonitis
There are two types of CPD therapy: continuous ambula-
tory peritoneal dialysis (CAPD) and continuous cycling
peritoneal dialysis (CCPD). The former modality involves
manual dialysis exchanges performed throughout the day
(usually three to five) while the latter modality is per-
formed continuously for approximately 8 to 10 hours at
night using an automated cycling device. CCPD therapy is
performed on the vast majority of CPD patients in the
United States.
There has been considerable debate regarding the effect of
either modality on the development of peritonitis. The
European Automated Peritoneal Dialysis Outcomes Study
reported higher rates of peritonitis for patients main-
tained on CAPD compared to patients maintained on
CCPD therapy [35]. Both our group and Yishak et al
reported similar rates of peritonitis for patients main-
tained on either modality [36,37]. And, Oo et al, using a
USRDS database between 1994 and 1997 noted that
CAPD therapy was associated with a lower risk of develop-
ment of a first episode of peritonitis after nine months of
CPD therapy [38].
Whether there are differences in the development and
outcome of peritonitis for patients maintained on CAPD
and CCPD is debatable. Yishak et al did note a trend
toward more adverse events among patients maintained
on CCPD compared to patients maintained on CAPD
(12% vs 6%, p = .21) [37]. Why might there exist a differ-
ence in outcomes?
While pharmacokinetic data concerning a multitude of
antimicrobial agents used to treat peritonitis for patients
maintained on CAPD has been well defined, there is a lit-
tle scientific data to support the ISPD recommendations
for treating patients with CCPD [24,38,39]. The ISPD rec-
ommends once-daily intraperitoneal (IP) administration
of antimicrobial agents for patients maintained on CCPD
or CAPD, administering the antibiotics during a long
dwell exchange. But because of augmented antibiotic
clearance with CCPD and the use of rapid exchanges dur-
ing nighttime cycling, adequate antibiotics levels may not
be achieved in the PD fluid during CCPD therapy (ManleyAnnals of Clinical Microbiology and Antimicrobials 2006, 5:6 http://www.ann-clinmicrob.com/content/5/1/6
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et al Semin Dial 15:418, 2002). For example, Manley et al
found once-daily loads of cefazolin and ceftazidime
resulted in levels below target MIC during cycling
exchanges [40]. Thus, some investigators have suggested
that all patients developing peritonitis be converted to
CAPD or that the rate of cycling be slowed while patients
are being treated for peritonitis.
Biofilm
Some episodes of peritonitis can be linked to poor patient
technique or a concomitant exit-site infection. But, many
episodes of peritonitis appear to be unrelated to obvious
causes. Some episodes, particularly those episodes involv-
ing S. aureus and S. epidermidis, recur or repeat despite
standard antibiotic therapy [15]. Furthermore, other epi-
sodes of peritonitis do not resolve unless the peritoneal
catheter is removed. Is there a nidus of infection that per-
sists? Is there a role for bacterial biofilm?
Costerton first described a sessile population of bacteria
that coexisted with free-floating, planktonic bacteria in
1978 [41]. It is known that these planktonic bacteria
attach themselves to a foreign body such, as the silastic
peritoneal catheter [42]. These attached bacteria become a
sessile population with an impenetrable glycocalyx matrix
coat. Bacterial cells within the sessile population commu-
nicate via a complex quorum sensing network which is
Table 1: 
Organism # Catheters 
Involved
Biofilm Organism 
Same?
Staphylococcus aureus 1Y e s
Enterococcus 1Y e s
Pseudomonas aeruginosa 3Y e s
Enterobacter 1Y e s
Bacteroides fragilis 1Y e s
Escherichia coli 1Y e s
Candida 1Y e s
Management of the Peritoneal Catheter During Peritonitis Figure 1
Management of the Peritoneal Catheter During Peritonitis.
Patient develops 
CPD associated 
peritonitis
Obtain culture, cell
count and start 
empiric
antibiotics*
Concomitant exit-
site or tunnel site 
abscess
All other 
organisms
Recurrent episode 
with same organism
Remove the peritoneal 
catheter, IV antibiotics
and temporary
hemodialysis through 
completion of antibiotic 
course
Organism isolated 
is Pseudomonas,
fungi, VRE or 
mycobacterium
Peritoneal fluid remains
cloudy after 5 days of 
antibiotic therapy:
remove the peritoneal 
catheter, IV antibiotics
and temporary
hemodialysis through 
completion of antibiotic 
course.
Remove the peritoneal 
catheter, IV antibiotics
and temporary
hemodialysis through 
completion of 
antibiotics.
Remove the 
peritoneal catheter, 
IV antibiotics and 
temporary
hemodialysis while 
site heals.Annals of Clinical Microbiology and Antimicrobials 2006, 5:6 http://www.ann-clinmicrob.com/content/5/1/6
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necessary for the production of biofilm [41,43]. Biofilm,
thus, is an example of a viable bacterial ecosystem.
Antibiotic penetration into this complex ecosystem
presents special problems. Do our current antimicrobial
therapies allow for penetration into the biofilm? Sepandj
examined this by studying the minimum biofilm erradica-
tion concentration (MBEC) of a first generation cepha-
losporin for coagulase-negative staphylococci [44]. This
group noted that the MBEC was particularly high, and,
that the percentage of resistant organisms increased when
patients experienced repeat infections.
Yet, Costerton et al note that the poor penetration of the
antibiotic into the complex biofilm matrix was not the
only hurdle to overcome in the eradication of biofilm
[41]. This group also has noted that bacteria within the
biofilm can differentiate into "protected phenotypic
states" permitting these sessile bacteria to further resist
standard antibiotic strategies.
We modified Costerton's techniques to examine biofilm
via confocal scanning light microscopy on the peritoneal
catheter [45]. A total of 10 peritoneal catheters were
removed and subsequently examined for biofilm. Biofilm
was identified on all ten catheters. The peritoneal cathe-
ters were removed because of peritonitis in eight patients
and because the peritoneal catheter was no longer needed
in two patients.
Table 1 identifies the individual organisms identified
within the biofilm of these removed catheters. All eight of
these catheters had the same organism isolated form the
biofilm that was isolated from the peritoneal effluent in a
previous episode of peritonitis.
These data suggest that bacterial biofilm does develop on
the catheter and does represent a concern for CPD
patients in terms of our ability to eradicate the infection
and in terms of the development of recurrent or repeat
peritonitis episodes. It is necessary that we better under-
stand the complex biological ecosystem of biofilm so that
better strategies can be developed to both eradicate the
biofilm. Studies need to be done to determine if our cur-
rent antibiotic strategies result in antibiotic penetration
within the biofilm matrix.
Conclusion
The percent of ESRD patients maintained on CPD therapy
has been declining. The reasons for this are unclear, but
may in fact be related to concerns about CPD-associated
peritonitis. Although the infection rate has declined in
recent years as the technology of CPD has advanced, peri-
tonitis remains a leading cause of both technique failure
and mortality for patients maintained on CPD therapy. It
is important that we improve our understanding of those
factors that are responsible for peritonitis and that we
develop better treatment paradigms for the management
of these infections.
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